Masako brings 30 years of commercial, general management and operational leadership experience in the biopharmaceutical industry.  She has devoted her career to improving rare disease patients’ lives, with a strong focus, drive and commitment to introducing innovative rare disease therapies across multiple therapeutic areas globally.

Masako has held several international and global senior leadership roles at Amylyx, Alnylam, Novelion, Genzyme and Genetics Institute. Throughout her tenure, she has had the honor and privilege of developing and launching over 20 innovative and transformative medicines for the rare disease and oncology communities globally.  She continues to be passionate about making a significant difference in patients’ lives, while always keeping patients and science at the center of what we do. 

Masako is a Mentor to the Fellows of The Termeer Foundation, Strategic Advisor to The Buffalo Initiative (non-profit patient organization) and Council Leader of the U.S.-Japan Council.